Open AccessThe Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date
Author(s) -
Win Min Oo,
Christopher B. Little,
Vicky Duong,
David J. Hunter
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s295224
Subject(s) - osteoarthritis , medicine , clinical trial , disease , intensive care medicine , drug development , articular cartilage , bioinformatics , drug , alternative medicine , pharmacology , pathology , biology
Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved disease-modifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.